The blood test used to detect prostate cancer may be more effective at preventing deaths — particularly among Black men — than previously thought, according to a study in NEJM Evidence.
Why it matters: Prostate cancer has one of the most pronounced disparities by race of any cancer, and Black men have historically been underrepresented in trials despite having double the risk of dying from it, the authors write.
Zoom in: Previous studies found prostate-specific antigen (PSA) screening prevented one death for every 23 men diagnosed, resulting in overdiagnoses and overtreatment.
The Goodbody Health Group Inc. is listed on the Canadian Securities Exchange (CSE), the Aquis Stock Exchange – Growth Market (AQSE) Apex segment, OTC, and Frankfurt Stock Exchange (FSE), providing current and prospective shareholders with multiple platforms in which to buy and sell Goodbody Health Group Inc. stock under the EPIC codes: CSE: GDBY / AQSE: GDBY / FRA: 484 / OTC: GDBYF).